New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues

Core Viewpoint - Penumbra is experiencing strong growth in its thrombectomy business, particularly in the U.S. market, but faces challenges from unfavorable currency movements and rising expenses [1][2][7]. Group 1: Business Performance - Penumbra's thrombectomy business is showing robust growth, with a 27.3% year-over-year increase in the U.S. for Q4 2024, driven by the adoption of its CAVT portfolio and new products [2]. - The U.S. VTE franchise reported a revenue growth of 41% year-over-year [2]. - Over the past three months, Penumbra's shares have increased by 16.7%, outperforming the industry, which saw a 5.6% decline [6]. Group 2: Product Launches and Innovations - The Element Vascular Access System was launched in January 2025, designed for venous thromboembolism treatments and compatible with the Lightning Flash 2.0 system [3]. - New products, including Lightning Bolt 12 and Lightning Bolt 6x with TraX, were launched in 2025 to enhance thrombus management [4]. - The company plans to focus on innovations within its Flash and Bolt product lines [4]. Group 3: International Market and Revenue - Approximately 24.5% of Penumbra's revenue in 2025 is expected to come from international markets, with plans to increase revenues and profitability in these regions [5]. - The company aims to introduce its advanced products, including RED catheters and Lightning series, to global teams [5]. Group 4: Cost and Expense Challenges - Penumbra's sales and costs are significantly affected by foreign exchange rate fluctuations, with 29% of consolidated revenues coming from non-U.S. markets in 2024 [7]. - The company faced a 7.3% increase in the cost of revenues and a 13.8% rise in selling, general, and administrative expenses year-over-year in Q4 2024 [8].